Ruxolitinib Good Manufacturer supply High Quality 941678-49-5
- Molecular Formula:C17H18N6
- Molecular Weight:306.37
- PKA:11.63±0.50(Predicted)
- PSA：83.18000
- Density:1.40g/cm3
- LogP:3.46638
Ruxolitinib (941678-49-5) Usage
In November 2011, the U.S. FDA approved ruxolitinib (INCB018424) for the treatment of patients with intermediate or high-risk myelofibrosis. Ruxolitinib is an ATP-competitive inhibitor of JAK1 and JAK2 (IC50's of 3.3±1.2 nM and 2.8±1.2 nM, respectively) and inhibition occurs regardless of the JAK2V617F mutational status. Ruxolitinib is a moderately potent inhibitor of the related JAK, TYK2 (IC50=19±3.2 nM) but is selective versus JAK3 (IC50=428±243 nM). It was also selective versus a panel of 26 other kinases at concentrations approximately 100-fold the IC50 of JAK1 and JAK2. Inhibition of JAK1 and JAK2 downregulates the JAK-signal transducer and activator of transcription (STAT) pathway, inhibiting myeloproliferation, inducing apoptosis, and reducing numerous cytokine plasma levels.
How to get the best price on Ruxolitinib?
Zibo Hangyu Biotechnology Development Co., Ltd is a quality supplier and manufacturer of Ruxolitinib . You can buy high quality, low price Ruxolitinib 941678-49-5 here.
Zibo Hangyu Biotechnology Development Co., Ltd. is a comprehensive chemical enterprise focusing on fine chemical products and pharmaceutical intermediates, integrating research and development, production and sales. The company is equipped with advanced equipment quality inspection and research center. At the same time, the company has excellent talents with rich experience in process development and quality control. To provide customers with total solutions from raw material processing to chemical synthesis systems. The company has established a standardized and perfect quality standard system to provide stable and high quality production and service.
Milestones
- 2012yearThe company was founded, began to engage in the production and supply of chemical raw materials
- 2014yearExpand the scale of production, pharmaceutical raw materials production workshop was established
- 2016yearCooperated with domestic and foreign chemical platforms to promote self-produced and high-end pharmaceutical intermediates
- 2019yearIn recent years to participate in the international pharmaceutical raw materials exhibitions
- 2023yearBusiness continues to expand, Production and Sales teams continue to grow
- 2026yearPlans to set up foreign branches
